Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Genomma Lab Internacional, S.A.B. de C.V.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Genomma Lab Internacional, S.A.B. de C.V.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Its low valuation, with P/E ratio at 5.08 and 6.1 for the ongoing fiscal year and 2027 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.92 for the 2026 fiscal year.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Genomma Lab Internacional, S.A.B. de C.V.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Most analysts recommend that the stock should be sold or reduced.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Genomma Lab Internacional, S.A.B. de C.V. SectorMexico

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
752M
A
1,024B
A
663B -
BBB
- -
453B
AA
-
352B
AA
304B
AAA
252B
A
236B
A
206B
A
187B
AA
Average 367.91B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. LAB B Stock
  4. Ratings Genomma Lab Internacional, S.A.B. de C.V.